Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 3/20 | 0.49 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26361947 | 0.93 | PLD1 (0.51) | GRM1PLD1GRIN2BCHRNB2CHRNA4 | |
| SCHEMBL30734163 | 0.93 | PLD1 (0.51) | GRM1PLD1GRIN2BCHRNB2CHRNA4 | |
| SCHEMBL13149760 | 0.76 | PLD1 (0.51) | GRM1PLD1GRIN2BKDM4EALDH1A1 | |
| SCHEMBL31400617 | 0.76 | PLD1 (0.51) | GRM1PLD1GRIN2BKDM4EALDH1A1 | |
| SCHEMBL4661349 | 0.76 | PLD1 (0.51) | GRM1PLD1GRIN2BKDM4EALDH1A1 | |
| SCHEMBL3568341 | 0.74 | CHRNB2 (0.53) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL3578509 | 0.73 | CHRNB2 (0.51) | CHRNB2CHRNA4 | |
| SCHEMBL23875353 | 0.73 | PLD1 (0.52) | GRM1PLD1GRIN2BKDM4EALDH1A1 | |
| SCHEMBL2002068 | 0.73 | PLD1 (0.52) | GRM1PLD1GRIN2BKDM4EALDH1A1 | |
| SCHEMBL16059500 | 0.73 | DPP4 (0.58) | GRM1PLD1GRIN2BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687523-B2 | 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists | NEUROSEARCH A/S (DK) | 2010-03-30 | — | — | US | claimed |
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | GLORIANA THERAPEUTICS, INC. | 2009-01-01 | — | — | US | claimed |
| EP-1987031-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NeuroSearch A/S (DK) | 2008-11-05 | — | — | EP | claimed |
| WO-2007090888-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NEUROSEARCH A/S (DK) | 2007-08-16 | — | — | WO | claimed |
| US-7687523-B2 | 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists | NEUROSEARCH A/S (DK) | 2010-03-30 | — | — | US | disclosed |
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | GLORIANA THERAPEUTICS, INC. | 2009-01-01 | — | — | US | disclosed |
| EP-1987031-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NeuroSearch A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007090888-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NEUROSEARCH A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | CHRNA3, CHRNA10, CHRNB3 | GRM1 235/4885PLD1 1879/4885GRIN2B 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.